Cybercriminals are targeting pharmaceutical companies at an increasing rate, spurred on by the high value of their intellectual property and sensitive data. The sector's complex ecosystem, characterized by a mix of legacy systems and new technologies, creates numerous vulnerabilities. Cyber threats have evolved, with attackers now focusing on data theft and system manipulation rather than merely deploying ransomware. The consequences of successful cyberattacks are severe, impacting drug formulations, intellectual property, clinical trials, company reputation, and revenue. As such, pharmaceutical companies must adopt a holistic cybersecurity framework that encompasses not just information technology (IT) but also operational technology (OT) and supply chain partners.

Join for free to read